Facts & Figures

1.9 million
New Incidents of Colon Cancer*

*Source: GLOBOCAN 2020
50 million
Colonoscopies Performed
Worldwide*

*Numbers for the US, Canada, Germany, France, Italy, Spain, the UK, Japan, China, South Korea, Australia and India.
As of 2019
100
Diseases or Conditions Treated

At Olympus we have versatile medical devices
with the ability to treat approximately
100* diseases or conditions

*As of March 2022
TOP 3
Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach
- Three cancers from the top 5* highest incidence of cancers
*Top 3 highest incidence of cancers excluding breast and prostate cancer, as of March 2022.
Source: GLOBOCAN 2020
32,844
Employees Worldwide^*1

*1 : As of March 2023

38
Countries or Regions^*2

*2: As of December 2022
¥881.9 bn
Total Medical
Revenue FY2023*

Medical Business occupies
the largest part of our revenue

*Figures are fiscal year revenues as of March 2023
70%
Global Market Share*

Olympus is the leader in
gastrointestinal endoscopic equipment

*As of Oct 2022
291
Awards

Since 1966, Olympus has been consistently
honored with national and international design
awards for its innovative product designs.*

*As of March 2022
17,000
Patents

across our product portfolio*

*As of March 2022
CO2“0”
Net zero CO2 emissions by 2030

We set as a target of achieving net zero CO2 emissions by 2030 from our site operations
TOP 100
Global Innovator

Since 2012 to 2020, and in 2022 and
2023, Olympus has been awarded
as one of the top 100 most
innovative companies in the world.
https://clarivate.com/top-100-innovators/